Compounds and methods for the treatment or prevention of

1. A compound according to formula I:

wherein:

R 1 is optionally substituted C 3-12 cycloalkyl, optionally substituted C 4-12 cycloalkenyl, optionally substituted —C(O)—C 3-12 cycloalkyl, optionally substituted —C(O)—C 4-12 cycloalkenyl, optionally substituted 5 to 12 member spiroheterocycloalkyl, or optionally substituted 8 to 12 member spiroheterocycloalkenyl, wherein when R 1 is optionally substituted 5 to 12 member spiroheterocycloalkyl the cycloalkyl moiety is directly attached to the 5-position of the thiophene ring, and when R 1 is optionally substituted 8 to 12 member spiroheterocycloalkenyl the cycloalkenyl moiety is directly attached to the 5-position of the thiophene ring;

Z is H, halogen, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, or optionally substituted C 2-6 alkynyl;

X is:

M is:

or a bond;

R 2 , R 3 and R 6 are each independently H, optionally substituted C 1-12 alkyl, optionally substituted C 2-12 alkenyl, optionally substituted C 2-12 alkynyl, optionally substituted C 6-14 aryl, optionally substituted C 7-16 aralkyl, optionally substituted 5-12 member heteroaryl, optionally substituted 6-18 member heteroaralkyl, optionally substituted 3-12 member heterocycle, or optionally substituted 4-18 member heterocycle-alkyl;

R 4 and R 5 are each independently H, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, or optionally substituted C 2-6 alkynyl;

Y 1 is a bond, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, or optionally substituted C 2-6 alkynyl;

Y is COOR 9 , COCOOR 9 , P(O)OR a OR b , S(O)OR 9 , S(O) 2 OR 9 , tetrazole, CON(R 9 )CH(R 9 )COOR 9 , CONR 10 R 11 , CON(R 9 )—SO 2 —R 9 , CONR 9 OH, or halogen;

R 9 , R 10 and R 11 are each independently chosen from H, optionally substituted C 1-12 alkyl, optionally substituted C 2-12 alkenyl, optionally substituted C 2-12 alkynyl, optionally substituted C 6-14 aryl, optionally substituted C 7-16 aralkyl, optionally substituted 5-12 member heteroaryl, optionally substituted 6-18 member heteroaralkyl, optionally substituted 3-12 member heterocycle, or optionally substituted 4-18 member heterocycle-alkyl,

or R 10 and R 11 are taken together with the nitrogen atom to form an optionally substituted 3 to 10 member heterocycle or an optionally substituted 5-12 member heteroaryl; and

R a and R b are each independently H, optionally substituted C 1-12 alkyl, optionally substituted C 2-12 alkenyl, optionally substituted C 2-12 alkynyl, optionally substituted C 6-14 aryl, optionally substituted C 7-16 aralkyl, optionally substituted 5-12 member heteroaryl, optionally substituted 6-18 member heteroaralkyl, optionally substituted 3-12 member heterocycle, or optionally substituted 4-18 member heterocycle-alkyl,

or R a and R b are taken together with the oxygen atoms to form an optionally substituted 5 to 10 member heterocycle, or an optionally substituted 5-12 member heteroaryl; or

a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 , wherein said compound is of formula IA:

or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof.

3. A compound according to claim 1 , wherein said compound is of formula IC:

or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof.

4. A compound according to claim 1 , wherein X is

and M is

or a bond.

5. A compound according to claim 3 , wherein M is

6. A compound according to claim 4 , wherein M is

7. A compound according to claim 1 , wherein Y 1 is CH 2 , C═CH, CH 2 —CH 2 or a bond.

8. A compound according to claim 1 , wherein Y 1 is a bond.

9. A compound according to claim 1 , wherein Y is COOR 9 , CONR 10 R 11 or CON(R 9 )CH(R 9 )—COOR 9 .

10. A compound according to claim 9 , wherein Y is COOR 9 , CONR 10 R 11 or CONR 9 CH 2 COOR 9 .

11. A compound according to claim 9 , wherein Y is COOH, CONH 2 , CONHCH 2 COOH, or COOCH 3 .

12. A compound according to claim 1 , wherein Y 1 —Y is COOH.

13. A compound according to claim 1 , wherein, R a , R b , R 9 , R 10 , and R 11 are each independently H or optionally substituted C 1-6 alkyl.

14. A compound according to claim 13 , wherein, R a , R b , R 9 , R 10 , and R 11 are each independently H or methyl.

15. A pharmaceutical combination comprising at least one compound according to claim 1 and at least one pharmaceutically acceptable carrier or excipient.

16. A pharmaceutical combination according to claim 15 , further comprising at least one additional agent selected from viral serine protease inhibitors, viral polymerase inhibitors, viral helicase inhibitors, immunomodulating agents, antioxidant agents, antibacterial agents, therapeutic vaccines, hepatoprotectant agents, antisense agents, inhibitors of HCV NS2/3 protease and inhibitors of internal ribosome entry site (IRES).

17. A method for treating a Flaviviridae viral infection in a host comprising administering to the host a therapeutically effective amount of at least one compound according to claim 1 .